In The News,

Physician-Administered Drug Commercialization

Provided expert-informed insights and predictions related to recent commercial market developments and trends that threaten the buy-and-bill structure for physician-administered drugs. Explained various stakeholder viewpoints and actions taken related to the commercial market physician-administered drug developments. Developed mitigation strategies that stakeholders could pursue to defend the buy-and-bill framework.